
# Section Four: Symptom Control and Palliative Care
Competencies articulated in this section focus on the ability of a radiation oncologist to:
- Manage common symptoms and conditions that occur in patients with cancer
- Provide holistic management to the terminally ill patient.

All competencies within Section Four require a detailed knowledge and the ability to apply this knowledge in clinical settings [D]. A [G] indicates more general knowledge, and minimal application of this knowledge, is required.

## CANCER RELATED SYMPTOMS AND TREATMENT SIDE-EFFECTS

### 1 Anxiety and depression
The trainee is able to:
- [ ] 1.1 List the risk factors for cancer patients developing depression or anxiety
- [ ] 1.2 Discuss the difficulties associated with the diagnosis of depression in the cancer patient
- [ ] 1.3 Describe the cognitive and physical symptoms of depression that aid in diagnosis
- [ ] 1.4 Recognise that depression and anxiety in the cancer patient is best managed by a combination of drugs, supportive psychotherapy and cognitive behavioural techniques
- [ ] 1.5 Refer patients requiring urgent and routine psychiatric assessment
- [ ] 1.6 Prescribe appropriate antidepressants and anxiolytics in the context of disease burden, recognising that drug selection is dependent on the patient’s symptoms, intercurrent medical problems, the drug side- effect profile and potential interactions with other medications. [G]

### 2 Bleeding
The trainee is able to:
- [ ] 2.1 Describe risk factors and common causes of bleeding in patients with malignancy
- [ ] 2.2 Perform a focused history and examination of patients with suspected bleeding
- [ ] 2.3 Determine the severity of bleeding and potential impact on prognosis and quality of life
- [ ] 2.4 Describe pharmacological, surgical, radiation and supportive options for patients with uncontrolled bleeding
- [ ] 2.5 Formulate a management plan and liaise with appropriate medical specialities
- [ ] 2.6 Devise an action plan for the management of patients at risk of catastrophic bleeding where intervention other than comfort measures is not warranted.

### 3 Bowel obstruction
The trainee is able to:
- [ ] 3.1 Describe the aetiology of malignant and treatment-related small and large bowel obstruction
- [ ] 3.2 Describe the clinical features of sub-acute bowel obstruction
- [ ] 3.3 Select and interpret radiological investigations to ascertain the level and degree of obstruction
- [ ] 3.4 Manage patients using conservative therapy including nasogastric tube, gut rest, IV fluids, correction of electrolyte imbalance, analgesia and antiemetics, as indicated
- [ ] 3.5 Refer patients for surgical opinion, including palliative procedures such as venting gastrostomies or endoscopic stents
- [ ] 3.6 Discuss the use of antisecretory agents and steroids in the palliative patient who is unsuitable for surgery. [G]

### 4 Cancer pain
The trainee is able to:
- [ ] 4.1 Discuss the pathophysiology and the different types of cancer pain, i.e. somatic, visceral, neuropathic and psychological [G]
- [ ] 4.2 Take a pain history eliciting the quality/severity, precipitating factors, temporal factors and site and/or radiation of pain
- [ ] 4.3 Describe common pain syndromes (e.g. plexopathy, spinal cord compression)
- [ ] 4.4 Describe the location of dermatomes
- [ ] 4.5 Select or review investigations in order to determine the likely causes and severity of the pain
- [ ] 4.6 Identify and use validated pain assessment tools
- [ ] 4.7 Discuss the importance of a multidisciplinary approach in achieving adequate analgesia
- [ ] 4.8 Pharmacological management:
    - [ ] 4.8.1 Describe the World Health Organisation (WHO) analgesic ladder
    - [ ] 4.8.2 Prescribe non-opiate analgesia, anticipate and manage related side-effects
    - [ ] 4.8.3 Prescribe common opiate analgesics, including selection of most appropriate drug and route of administration, differentiation of the needs of long-acting and breakthrough analgesia, demonstration of an understanding of equianalgesic dosing; and anticipation and management of potential side-effects
    - [ ] 4.8.4 Demonstrate an understanding of the use of syringe drivers and subcutaneous access in the palliative patient
    - [ ] 4.8.5 Describe the role of adjuvant analgesics (e.g. steroids, anti-epileptics, antidepressants, bisphosphonates)
    - [ ] 4.8.6 Assess patient response to a chosen analgesic regimen and refer patient to a palliative care or pain specialist, if required.
- [ ] 4.9 Non-pharmacological management: [G]
    - [ ] 4.9.1 Discuss the role of non-pharmacological physical approaches (e.g., splinting or immobilisation, transcutaneous electrical nerve stimulation (TENS), acupuncture, physiotherapy)
    - [ ] 4.9.2 Describe common anaesthetic and palliative surgical procedures that may be used to control cancer-related pain
    - [ ] 4.9.3 Discuss the psychological interventions that may be used for pain management.
- [ ] 4.10 Radiation therapy
    - [ ] 4.10.1 Describe clinical settings where radiation is used to control pain and for each setting ascribe an expected response rate after treatment
    - [ ] 4.10.2 Determine suitable dose fractionation schedule to manage pain, dependent on the patient’s prognosis and tumour characteristics.

### 5 Constipation
The trainee is able to:
- [ ] 5.1 Identify the common causes of constipation in cancer patients, including pharmacological causes such as opiates
- [ ] 5.2 Recognise that the cause of constipation is often multifactorial
- [ ] 5.3 Perform an abdominal and rectal assessment
- [ ] 5.4 Differentiate the clinical symptoms and radiologic signs of constipation vs. bowel obstruction
- [ ] 5.5 Describe the modes of action of different aperients (e.g. oral softeners, peristaltic stimulators, per rectum laxatives)
- [ ] 5.6 Manage a patient with constipation, prescribing appropriate aperients and follow up accordingly to monitor effectiveness.

### 6 Delirium and agitation
The trainee is able to:
- [ ] 6.1 Describe the clinical features of acute delirium
- [ ] 6.2 Describe common causes of acute delirium in the cancer patient
- [ ] 6.3 Differentiate between acute delirium and terminal restlessness
- [ ] 6.4 Address any reversible causes of acute delirium
- [ ] 6.5 Discuss the use of non-pharmacological strategies for re-orientating and calming a delirious or agitated patient
- [ ] 6.6 Discuss the use of antipsychotics, sedatives and hypnotics to patients experiencing acute delirium and agitation.

### 7 Diarrhoea
The trainee is able to:
- [ ] 7.1 Identify the common causes of diarrhoea in the cancer patient
- [ ] 7.2 Distinguish between true diarrhoea and tenesmus
- [ ] 7.3 Assess patient hydration status and determine whether patients require intravenous rehydration/admission
- [ ] 7.4 Identify situations where patients require stool and blood workup
- [ ] 7.5 Prescribe pharmacological intervention as appropriate, and describe regimens commonly used to manage radiation-induced diarrhoea
- [ ] 7.6 In the setting of severe treatment-related or tumour-related diarrhoea, prescribe parenteral antisecretory agents such as octreotide.

### 8 Dyspnoea
The trainee is able to:
- [ ] 8.1 Discuss the causes of cancer-related dyspnoea
- [ ] 8.2 Assess the severity of dyspnoea and identify situations where urgent inpatient management is required
- [ ] 8.3 Select or review investigations in order to identify potentially reversible causes of dyspnoea
- [ ] 8.4 Provide information to patients in relation to the risks and benefits of an intervention in the palliative setting to assist them to make informed decisions with regard to treatment
- [ ] 8.5 Recognise that the cause of dyspnoea is often multifactorial, and that treatment is dictated by the suspected cause(s)
- [ ] 8.6 Pharmacological management:
    - [ ] 8.6.1 Prescribe medication (e.g. oxygen therapy, steroids, opiates, anticoagulants and benzodiazepines, as indicated).
- [ ] 8.7 Non-pharmacological management
    - [ ] 8.7.1 Arrange blood transfusion, pleural tap, pleurodesis, and paracentesis, as indicated
    - [ ] 8.7.2 Discuss palliative strategies to decrease the sensation of dyspnoea in patients with non-reversible aetiology (e.g. relaxation, cognitive behavioural therapies and environmental strategies).

### 9 Endocrine dysfunction
For the hypothalamic-pituitary axis, thyroid, pancreatic and adrenal endocrine systems, the trainee is able to:
- [ ] 9.1 Discuss risk factors for dysfunction after cancer treatment
- [ ] 9.2 Describe clinical signs and symptoms of dysfunction in adult and paediatric populations
- [ ] 9.3 Request and interpret appropriate investigations to confirm the diagnosis and assess progress
- [ ] 9.4 Discuss the role of replacement hormone therapies and refer for endocrinological follow-up as required. [G]

### 10 Fatigue, cachexia and anorexia
The trainee is able to:
- [ ] 10.1 Describe their multifactorial aetiology in the cancer patient
- [ ] 10.2 Discuss the pathophysiology of the anorexia-cachexia syndrome
- [ ] 10.3 Assess the severity of symptoms and identify potentially reversible factors
- [ ] 10.4 Evaluate these symptoms in the context of prognosis and end-of-life care
- [ ] 10.5 Non-pharmacological management:
    - [ ] 10.5.1 Discuss the role of exercise in cancer-related fatigue
    - [ ] 10.5.2 Refer patients to relevant allied health professionals for physical and psychological therapy or dietary advice and/or supplementation.
- [ ] 10.6 Pharmacological management:
    - [ ] 10.6.1 Review current medications that may be contributing to symptoms and amend as required
    - [ ] 10.6.2 Prescribe medications to improve sleep, including psychostimulants, steroids, analgesia and transfusion, as indicated.

### 11 Fever and neutropenic sepsis
The trainee is able to:
- [ ] 11.1 Describe the aetiology of fever in patients with cancer
- [ ] 11.2 Identify patients at risk of infection and consider prophylactic measures
- [ ] 11.3 Identify patients at risk of developing febrile neutropenia (FN), particularly with respect to timing and delivery of cytotoxic chemotherapy
- [ ] 11.4 Identify the unwell patient and those at risk of rapid deterioration
- [ ] 11.5 Prescribe appropriate intravenous antibiotic regimens and supportive measures for patients with FN according to local and national management guidelines
- [ ] 11.6 Monitor patient progress and response to therapy.

### 12 Genitourinary symptoms – obstructive/irritative symptoms and bleeding
The trainee is able to:
- [ ] 12.1 Assess urinary function and use specific tools (e.g. the international prostate symptom score (IPSS))
- [ ] 12.2 Review patient medications and assess impact on urinary symptoms
- [ ] 12.3 Evaluate a patient for suspected urinary retention and define the cause of obstruction
- [ ] 12.4 Discuss the aetiology of genitourinary symptoms in cancer patients, select investigations and refer for surgical evaluation, when appropriate
- [ ] 12.5 Discuss the pharmacological management of obstructive and irritative urinary symptoms
- [ ] 12.6 Discuss the role of urethral and suprapubic catheters in the management of outlet obstruction and urinary incontinence
- [ ] 12.7 Discuss the treatment of tumour-related haematuria, including the management of pre-existing anticoagulation
- [ ] 12.8 Discuss the role of surgery in the management of late radiation genitourinary side-effects, i.e. fistulae, strictures, hydronephrosis and haematuria.

### 13 Gonadal dysfunction
The trainee is able to:
- [ ] 13.1 Discuss risk factors for treatment-related infertility
- [ ] 13.2 Discuss risk factors for loss of function after treatment
- [ ] 13.3 Describe effects of reduced sex hormone production on the body
- [ ] 13.4 Describe fertility-preservation options according to the age and sex of the patient [G]
- [ ] 13.5 Discuss the role of replacement therapies according to age and sex of the patient, recognising situations where replacement is contraindicated. [G]

### 14 Headache and raised intracranial pressure
Trainee is able to:
- [ ] 14.1 Differentiate between benign and malignant causes of headache
- [ ] 14.2 Elicit the signs and symptoms associated with raised intracranial pressure
- [ ] 14.3 Identify patients with potentially life-threatening causes of headache (e.g. acute haemorrhage, obstructive hydrocephalus at risk of cerebral herniation) for inpatient assessment and management
- [ ] 14.4 Prescribe steroid therapy and anticipate side-effects, as indicated
- [ ] 14.5 Prescribe a suitable analgesic and antiemetic regimen depending on severity of headache
- [ ] 14.6 Manage patients experiencing tumour or treatment-related seizures
- [ ] 14.7 Describe surgical procedures available to manage raised intracranial pressure, and refer patients, as appropriate.

### 15 Hypercalcaemia
The trainee is able to:
- [ ] 15.1 Describe the causes and pathophysiology of hypercalcaemia in the setting of malignancy
- [ ] 15.2 Recognise the symptoms and signs of hypercalcaemia
- [ ] 15.3 Identify common medications that may exacerbate hypercalcaemia
- [ ] 15.4 Assess hydration and renal function
- [ ] 15.5 Describe the prognostic significance of hypercalcaemia in the metastatic setting
- [ ] 15.6 Formulate a management plan for a patient with hypercalcaemia
- [ ] 15.7 Appropriately prescribe denosumab or bisphosphonate therapy
- [ ] 15.8 Monitor patient progress and evaluate response to therapy.

### 16 Lymphoedema
The trainee is able to:
- [ ] 16.1 Describe the clinical symptoms and signs of lymphoedema
- [ ] 16.2 Discuss the tumour and treatment-related aetiology of lymphoedema
- [ ] 16.3 Assess the degree of lymphoedema as it relates to physical, functional and psychosocial impacts on the patient and refer early to allied health services
- [ ] 16.4 Describe the different management strategies available (e.g. manual lymphatic drainage, compression bandaging/garments, exercise [G])
- [ ] 16.5 Educate the patient on preventative strategies to reduce the risk of lymphoedema [G]
- [ ] 16.6 Educate patients on preventative skin care and manage skin infections. [G]

### 17 Metabolic dysfunction
The trainee is able to:
- [ ] 17.1 Describe clinical and laboratory features of metabolic syndrome and the relation to treatment and non- treatment-related risk factors for cardiovascular disease
- [ ] 17.2 Discuss treatment and non-treatment-related determinants of bone metabolism
- [ ] 17.3 Define osteoporosis and osteopaenia, and explain their clinical relevance in terms of fracture risk
- [ ] 17.4 Outline various preventative strategies to reduce the risk of cardiovascular events in patients with treatment-related metabolic syndrome and devise an appropriate strategy for the patient
- [ ] 17.5 Define osteoporosis and osteopenia, and explain their clinical relevance in terms of fracture risk
- [ ] 17.6 Manage patients to restore metabolic function, including the use of pharmacological, non- pharmacological and lifestyle interventions to reduce fracture risk associated with endocrine therapies.

### 18 Nausea and vomiting
The trainee is able to:
- [ ] 18.1 Discuss the causes of cancer-related and treatment-related nausea and vomiting
- [ ] 18.2 Predict the risk of radiation-induced emesis according to anatomical site and dose prescription
- [ ] 18.3 Pharmacological management:
    - [ ] 18.3.1 Discuss the multifactorial nature of nausea and vomiting and the mode of action of commonly used anti-emetic agents
    - [ ] 18.3.2 Prescribe appropriate anti-emetic medication (e.g. hydroxytryptamine receptor blockers (5- HT3), dopamine antagonists, haloperidol and steroids).
- [ ] 18.4 Non-pharmacological management
    - [ ] 18.4.1 Determine the suitability of surgical intervention for patients who require treatment for uncontrolled nausea and vomiting.

### 19 Oral cavity and pharyngeal mucositis, oesophagitis and dysphagia
The trainee is able to:
- [ ] 19.1 Discuss the impact of radiation on the upper aerodigestive tract, including expected timing and duration of symptoms
- [ ] 19.2 Discuss the impact of different systemic therapy agents on the upper aerodigestive tract
- [ ] 19.3 Assess the patient presenting with suspected oropharyngeal and oesophageal fungal/viral infection
- [ ] 19.4 Refer patients to a dietician and speech therapy, as appropriate
- [ ] 19.5 Determine the suitability of percutaneous endoscopic gastroscopy (PEG) insertion
- [ ] 19.6 Apply evidence-based clinical practice guidelines for patients with oral and gastrointestinal mucositis (e.g. MASCC/ISOO guidelines)
- [ ] 19.7 Prescribe medications such as analgesia, antifungals, antivirals, medicated mouthwashes, topical anaesthetics and proton pump inhibitors, as indicated
- [ ] 19.8 Suggest supportive non-pharmacological interventions such as standard oral care protocols and humidified air to patients, as appropriate
- [ ] 19.9 Refer patients for endoscopic dilatation or stenting to manage malignant and treatment-related oesophageal stricture, as appropriate.

### 20 Proctitis
The trainee is able to:
- [ ] 20.1 Assess the risk of radiation proctitis based on patient and treatment factors
- [ ] 20.2 Prescribe pharmacological interventions for patients with acute and chronic radiation-induced proctitis (e.g. hydrocortisone suppositories and retention enemas, sucralfate enemas)
- [ ] 20.3 Discuss the risks and benefits of the different techniques used to treat rectal bleeding secondary to chronic radiation proctitis (e.g. endoscopic argon plasma coagulation and topical formaldehyde).

### 21 Sexual dysfunction after cancer treatment
The trainee is able to:
- [ ] 21.1 Identify patients at risk of treatment-related sexual dysfunction
- [ ] 21.2 Discuss the utility of screening tools for sexual dysfunction in at-risk populations [G]
- [ ] 21.3 Identify the endocrine, physical and psychological impact that cancer treatment may have on sexual dysfunction
- [ ] 21.4 Describe psychological, pharmacological and surgical approaches to treatment depending on the underlying cause
- [ ] 21.5 Discuss the role of vaginal dilators after radiation therapy.

### 22 Skin complications
The trainee is able to:
- [ ] 22.1 Describe the factors that predispose a patient to radiation therapy skin reactions and/or increase the severity of a skin reaction
- [ ] 22.2 Describe the possible skin reactions that may result from systemic cancer treatment [G]
- [ ] 22.3 Assess and institute appropriate skincare management during a course of radiation therapy or systemic therapy
- [ ] 22.4 Identify patients experiencing an unexpected skin reaction and investigate and manage appropriately
- [ ] 22.5 Discuss the role of medications in the treatment of skin complications (e.g. oral and topical antibiotics, analgesia and antifungals)
- [ ] 22.6 Refer patients to wound care specialist nurses, community nurses and surgeons.

### 23 Tumour lysis syndrome [G and S]
The trainee is able to:
- [ ] 23.1 Explain the pathophysiology of tumour lysis syndrome
- [ ] 23.2 Describe the symptoms, signs and possible complications of tumour lysis syndrome
- [ ] 23.3 Identify patients at high risk for the development of tumour lysis syndrome
- [ ] 23.4 Discuss a regimen for the prophylaxis of tumour lysis syndrome
- [ ] 23.5 List the biochemical parameters that should be monitored in patients at risk for tumour lysis syndrome
- [ ] 23.6 Assess severity of established tumour lysis syndrome and describe management.

### 24 Venous Thromboembolism (VTE)
The trainee is able to:
- [ ] 24.1 Identify patients at high risk of developing VTE and discuss preventative measures in the context of established guidelines
- [ ] 24.2 Describe the symptoms and signs of VTE and perform a focused examination to assess severity
- [ ] 24.3 Select appropriate investigations to confirm or exclude a diagnosis of VTE
- [ ] 24.4 Counsel patients on the associated risks of VTE and anticoagulation therapy
- [ ] 24.5 Prescribe therapeutic anticoagulation where appropriate and liaise with other medical/interventional specialties as needed for complex cases
- [ ] 24.6 Monitor patient progress and duration of treatment.

### 25 Xerostomia
The trainee is able to:
- [ ] 25.1 Assess the risk of developing xerostomia based on radiation therapy dosimetry
- [ ] 25.2 Assess the impact of xerostomia on nutritional status and dental hygiene
- [ ] 25.3 Be aware of medications that may exacerbate xerostomia, such as anticholinergics, antihistamines and antipsychotics
- [ ] 25.4 Manage patients with xerostomia, including the use of pharmacological and non-pharmacological gustatory stimulants, artificial saliva and dietary change
- [ ] 25.5 Refer patients to a speech pathologist, dietician and/or dentist for review, as appropriate.

## PALLIATIVE CARE

### 1 General
The trainee is able to:
- [ ] 1.1 Define the concept of palliative care, including the WHO definition
- [ ] 1.2 Provide a holistic treatment approach by involving palliative care, nursing care and allied health early in the course of illness for patients with metastatic disease or a high symptom burden
- [ ] 1.3 Discuss community and inpatient palliative care services and the eligibility criteria to receive care
- [ ] 1.4 Prescribe palliative radiation, taking into account the time to clinical response and the patient’s life expectancy, utilising short fractionation schedules, where possible
- [ ] 1.5 Discuss end-of-life issues with patients and their families, including the benefits of advanced health directives and do-not-resuscitate (DNR) orders
- [ ] 1.6 Establish goals of care that are in keeping with patient values and preferences
- [ ] 1.7 Acknowledge patients’ need for spiritual experience and observance of religious beliefs and assist with access to pastoral care if requested.

### 2 Prognostication in the palliative setting
The trainee is able to:
- [ ] 2.1 Discuss the importance of prognosis with regard to decision-making around delivery of potential therapies for the palliative patient
- [ ] 2.2 Discuss the patient and cancer-specific factors that influence prognosis
- [ ] 2.3 Discuss the site-specific and general models available to help predict prognosis in patients with advanced cancer
- [ ] 2.4 Be aware of tendency among physicians to overestimate prognosis
- [ ] 2.5 Discuss the benefit/side-effects ratio of commonly-delivered palliative radiation therapy treatments with respect to impact on quality of life (QOL)
- [ ] 2.6 Understand the concept of futile treatment and potential for harm to patients with limited life expectancy
- [ ] 2.7 Use validated prognostic tools to estimate predicted survival when devising a management plan for a palliative patient
- [ ] 2.8 Establish the patient’s wishes in the setting of poor prognosis with regard to potential treatments and impact on QOL
- [ ] 2.9 Involve the patient in the decision-making process and respect their wishes in the setting of refusal of treatment.

### 3 Management of the terminally ill patient and their family
The trainee is able to:
- [ ] 3.1 Identify the symptoms and signs of the terminal phase of patients with advanced cancer
- [ ] 3.2 Outline the holistic care needs for dying patients and their families with respect to:
    - [ ] 3.2.1 Physical care
    - [ ] 3.2.2 Emotional support
    - [ ] 3.2.3 Cultural/social aspects
    - [ ] 3.2.4 Spiritual/religious aspects.
- [ ] 3.3 Identify potential barriers/conflicts that may result in a sub-optimal experience of the dying process:
    - [ ] 3.3.1 Conflict/misunderstanding regarding DNR orders
    - [ ] 3.3.2 Requests for euthanasia (requires awareness of relevant state and national legislation)
    - [ ] 3.3.3 Conflict regarding withdrawing or withholding ‘active’ interventions
    - [ ] 3.3.4 Religious and cultural beliefs of the patient and family different from those of the treating physician.
- [ ] 3.4 Locate and initiate appropriate local ‘care of the dying’ pathways for patients and liaise with palliative care specialists, as necessary
- [ ] 3.5 Describe the management of commonly-occurring symptoms, including common medications, at the end of life, including:
    - [ ] 3.5.1 Progressive swallowing difficulties
    - [ ] 3.5.2 Mouth dryness/soreness
    - [ ] 3.5.3 ‘Death rattle’ and airway secretions
    - [ ] 3.5.4 Agitation and terminal restlessness.
- [ ] 3.6 Exhibit compassion and empathy for dying patients and their families and provide information regarding relevant duties for families around the time of death
- [ ] 3.7 Identify criteria for the pronouncement of death
- [ ] 3.8 Be aware of the legal requirements for death certification, including reporting of death to the coroner, when appropriate.
